Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

QUALITY OF LIFE IN A RANDOMIZED BREAST CANCER PREVENTION TRIAL OF LOW-DOSE TAMOXIFEN AND FENRETINIDE IN PREMENOPAUSAL WOMEN.

Serrano D, Gandini S, Guerrieri-Gonzaga A, Feroce I, Johansson H, Macis D, Aristarco V, Bonanni B, DeCensi A.

Cancer Prev Res (Phila). 2018 Oct 23. pii: canprevres.0073.2018. doi: 10.1158/1940-6207.CAPR-18-0073. [Epub ahead of print]

PMID:
30352838
2.

The recognition of the profession of Genetic Counsellors in Europe.

Cordier C, McAllister M, Serra-Juhe C, Bengoa J, Pasalodos S, Bjornevoll I, Feroce I, Moldovan R, Paneque M, Lambert D; All are member of the Board of the Genetic Nurses and Genetic Counsellors Professional Branch of the European Board of Medical Genetics.

Eur J Hum Genet. 2018 Sep 25. doi: 10.1038/s41431-018-0260-x. [Epub ahead of print] Review. No abstract available.

PMID:
30254214
3.

Erratum: BRCA1 homozygous unclassified variant in a patient with non-Fanconi anemia: A case report.

Bondavalli D, Malvestiti F, Pensotti V, Feroce I, Bonanni B.

Oncol Lett. 2018 Sep;16(3):3408. doi: 10.3892/ol.2018.9015. Epub 2018 Jun 25.

4.

Hereditary lobular breast cancer with an emphasis on E-cadherin genetic defect.

Corso G, Figueiredo J, La Vecchia C, Veronesi P, Pravettoni G, Macis D, Karam R, Lo Gullo R, Provenzano E, Toesca A, Mazzocco K, Carneiro F, Seruca R, Melo S, Schmitt F, Roviello F, De Scalzi AM, Intra M, Feroce I, De Camilli E, Villardita MG, Trentin C, De Lorenzi F, Bonanni B, Galimberti V.

J Med Genet. 2018 Jul;55(7):431-441. doi: 10.1136/jmedgenet-2018-105337. Epub 2018 Jun 21.

PMID:
29929997
5.

Clinical criteria revision for hereditary lobular breast cancer associated with E-cadherin germline mutations.

Corso G, De Scalzi A, Feroce I, Veronesi P, Bonanni B, Galimberti V.

Per Med. 2018 May 1;15(3):153-155. doi: 10.2217/pme-2017-0083. Epub 2018 May 10. No abstract available.

PMID:
29745790
6.

BRCA1 homozygous unclassified variant in a patient with non-Fanconi anemia: A case report.

Bondavalli D, Malvestiti F, Pensotti V, Feroce I, Bonanni B.

Oncol Lett. 2018 Mar;15(3):3329-3332. doi: 10.3892/ol.2017.7711. Epub 2017 Dec 28. Erratum in: Oncol Lett. 2018 Sep;16(3):3408.

7.

Prognostic impact of germline mutations in inherited cancer syndromes.

Corso G, Feroce I, Intra M, Veronesi P, Sacchini V, Bonanni B, Galimberti V.

Future Oncol. 2017 Oct;13(24):2125-2127. doi: 10.2217/fon-2017-0296. Epub 2017 Oct 6. No abstract available.

PMID:
28984488
8.

Hereditary diffuse gastric cancer in two families: A case report.

Feroce I, Serrano D, Biffi R, Andreoni B, Galimberti V, Sonzogni A, Bottiglieri L, Botteri E, Trovato C, Marabelli M, Ranzani GN, Bonanni B.

Oncol Lett. 2017 Aug;14(2):1671-1674. doi: 10.3892/ol.2017.6354. Epub 2017 Jun 8.

9.

The perceived impact of the European registration system for genetic counsellors and nurses.

Paneque M, Moldovan R, Cordier C, Serra-Juhé C, Feroce I, Pasalodos S, Haquet E, Lambert D, Bjørnevoll I, Skirton H.

Eur J Hum Genet. 2017 Sep;25(9):1075-1077. doi: 10.1038/ejhg.2017.84. Epub 2017 May 17.

10.

BRCA1/2 germline missense mutations: a systematic review.

Corso G, Feroce I, Intra M, Toesca A, Magnoni F, Sargenti M, Naninato P, Caldarella P, Pagani G, Vento A, Veronesi P, Bonanni B, Galimberti V.

Eur J Cancer Prev. 2018 May;27(3):279-286. doi: 10.1097/CEJ.0000000000000337.

PMID:
28277317
11.

A Randomized, Placebo-Controlled, Phase II, Presurgical Biomarker Trial of Celecoxib Versus Exemestane in Postmenopausal Breast Cancer Patients.

Aristarco V, Serrano D, Gandini S, Johansson H, Macis D, Guerrieri-Gonzaga A, Lazzeroni M, Feroce I, Pruneri G, Pagani G, Toesca A, Caldarella P, DeCensi A, Bonanni B.

Cancer Prev Res (Phila). 2016 May;9(5):349-56. doi: 10.1158/1940-6207.CAPR-15-0311. Epub 2016 Feb 29.

12.

Improved health perception after genetic counselling for women at high risk of breast and/or ovarian cancer: construction of new questionnaires--an Italian exploratory study.

Catania C, Feroce I, Barile M, Goldhirsch A, De Pas T, de Braud F, Boselli S, Adamoli L, Radice D, Rossi A, Spitaleri G, Noberasco C, Bonanni B.

J Cancer Res Clin Oncol. 2016 Mar;142(3):633-48. doi: 10.1007/s00432-015-2062-7. Epub 2015 Nov 17.

PMID:
26577826
13.

Development of a registration system for genetic counsellors and nurses in health-care services in Europe.

Paneque M, Moldovan R, Cordier C, Serra-Juhé C, Feroce I, Lambert D, Bjørnevoll I, Skirton H.

Eur J Hum Genet. 2016 Mar;24(3):312-4. doi: 10.1038/ejhg.2015.234. Epub 2015 Nov 4. No abstract available.

14.

Difficult choices for young patients with cancer: the supportive role of decisional counseling.

Chiavari L, Gandini S, Feroce I, Guerrieri-Gonzaga A, Russell-Edu W, Bonanni B, Peccatori FA.

Support Care Cancer. 2015 Dec;23(12):3555-62. doi: 10.1007/s00520-015-2726-5. Epub 2015 Apr 11.

PMID:
25862346
15.

E-cadherin germline mutation carriers: clinical management and genetic implications.

Corso G, Figueiredo J, Biffi R, Trentin C, Bonanni B, Feroce I, Serrano D, Cassano E, Annibale B, Melo S, Seruca R, De Lorenzi F, Ferrara F, Piagnerelli R, Roviello F, Galimberti V.

Cancer Metastasis Rev. 2014 Dec;33(4):1081-94. doi: 10.1007/s10555-014-9528-y. Review.

PMID:
25332147
16.

Complementary molecular approaches reveal heterogeneous CDH1 germline defects in Italian patients with hereditary diffuse gastric cancer (HDGC) syndrome.

Molinaro V, Pensotti V, Marabelli M, Feroce I, Barile M, Pozzi S, Laghi L, Serrano D, Bernard L, Bonanni B, Ranzani GN.

Genes Chromosomes Cancer. 2014 May;53(5):432-45. doi: 10.1002/gcc.22155. Epub 2014 Feb 3.

PMID:
24493355
17.

A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer.

Serrano D, Lazzeroni M, Gandini S, Macis D, Johansson H, Gjerde J, Lien E, Feroce I, Pruneri G, Sandri M, Bassi F, Brenelli F, Luini A, Cazzaniga M, Varricchio C, Guerrieri-Gonzaga A, DeCensi A, Bonanni B.

Breast Cancer Res. 2013 Jun 20;15(3):R47. doi: 10.1186/bcr3439.

18.

Rare variants in XRCC2 as breast cancer susceptibility alleles.

Hilbers FS, Wijnen JT, Hoogerbrugge N, Oosterwijk JC, Collee MJ, Peterlongo P, Radice P, Manoukian S, Feroce I, Capra F, Couch FJ, Wang X, Guidugli L, Offit K, Shah S, Campbell IG, Thompson ER, James PA, Trainer AH, Gracia J, Benitez J, van Asperen CJ, Devilee P.

J Med Genet. 2012 Oct;49(10):618-20. doi: 10.1136/jmedgenet-2012-101191.

PMID:
23054243
19.

Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk?

Cazzaniga M, Varricchio C, Montefrancesco C, Feroce I, Guerrieri-Gonzaga A.

J Biomed Biotechnol. 2012;2012:172897. doi: 10.1155/2012/172897. Epub 2012 Mar 5. Review.

20.

Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients.

Fumagalli C, Pruneri G, Possanzini P, Manzotti M, Barile M, Feroce I, Colleoni M, Bonanni B, Maisonneuve P, Radice P, Viale G, Barberis M.

Breast Cancer Res Treat. 2012 Jul;134(1):131-7. doi: 10.1007/s10549-011-1945-9. Epub 2012 Jan 8.

PMID:
22228432
21.

Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer.

Macis D, Gandini S, Guerrieri-Gonzaga A, Johansson H, Magni P, Ruscica M, Lazzeroni M, Serrano D, Cazzaniga M, Mora S, Feroce I, Pizzamiglio M, Sandri MT, Gulisano M, Bonanni B, Decensi A.

J Clin Oncol. 2012 Jan 10;30(2):151-7. doi: 10.1200/JCO.2011.35.2237. Epub 2011 Dec 12.

22.

Budesonide versus placebo in high-risk population with screen-detected lung nodules: rationale, design and methodology.

Lazzeroni M, Guerrieri-Gonzaga A, Serrano D, Varricchio MC, Veronesi G, Radice D, Feroce I, Nardi-Pantoli A, Lippman SM, Szabo E, Bonanni B.

Contemp Clin Trials. 2010 Nov;31(6):612-9. doi: 10.1016/j.cct.2010.08.006. Epub 2010 Aug 16.

23.

Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis.

Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P, Bernard L, Maisonneuve P, Gandini S.

Eur J Cancer. 2010 Aug;46(12):2275-84. doi: 10.1016/j.ejca.2010.04.018. Epub 2010 May 27. Review.

PMID:
20537530
24.

Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users.

Rondanina G, Puntoni M, Severi G, Varricchio C, Zunino A, Feroce I, Bonanni B, Decensi A.

J Clin Oncol. 2008 Mar 20;26(9):1537-43. doi: 10.1200/JCO.2007.13.6739.

PMID:
18349406
25.

Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT.

Serrano D, Mariani L, Mora S, Guerrieri-Gonzaga A, Cazzaniga M, Daldoss C, Ramazzotto F, Feroce I, Decensi A, Bonanni B.

Maturitas. 2006 Aug 20;55(1):69-75. Epub 2006 Feb 24.

PMID:
16500052

Supplemental Content

Loading ...
Support Center